Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Coagulation | 4 | 2023 | 23 | 1.810 |
Why?
|
| Factor XIa | 3 | 2022 | 4 | 1.210 |
Why?
|
| Anticoagulants | 4 | 2023 | 102 | 1.200 |
Why?
|
| Factor XIIa | 2 | 2023 | 2 | 1.060 |
Why?
|
| Thrombosis | 2 | 2022 | 63 | 0.850 |
Why?
|
| Pentamidine | 2 | 2019 | 9 | 0.820 |
Why?
|
| Fibrinolysis | 1 | 2019 | 2 | 0.690 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2019 | 37 | 0.670 |
Why?
|
| Lipid Bilayers | 3 | 2007 | 68 | 0.600 |
Why?
|
| Thermodynamics | 4 | 2010 | 216 | 0.570 |
Why?
|
| Membrane Proteins | 3 | 2014 | 517 | 0.520 |
Why?
|
| Antineoplastic Agents | 4 | 2015 | 803 | 0.500 |
Why?
|
| Histone Deacetylases | 1 | 2015 | 56 | 0.490 |
Why?
|
| Models, Molecular | 9 | 2015 | 808 | 0.460 |
Why?
|
| Prothrombin Time | 2 | 2023 | 10 | 0.400 |
Why?
|
| Biomimetic Materials | 1 | 2007 | 23 | 0.300 |
Why?
|
| Alamethicin | 1 | 2006 | 8 | 0.280 |
Why?
|
| Membrane Lipids | 1 | 2006 | 33 | 0.270 |
Why?
|
| Allosteric Site | 2 | 2022 | 11 | 0.260 |
Why?
|
| Neoplasms | 1 | 2015 | 1103 | 0.250 |
Why?
|
| Amides | 1 | 2005 | 68 | 0.240 |
Why?
|
| Catalytic Domain | 2 | 2022 | 109 | 0.230 |
Why?
|
| Thrombin Time | 2 | 2020 | 2 | 0.220 |
Why?
|
| Partial Thromboplastin Time | 2 | 2020 | 8 | 0.220 |
Why?
|
| Animals | 13 | 2023 | 15081 | 0.220 |
Why?
|
| Humans | 15 | 2023 | 37093 | 0.210 |
Why?
|
| Factor XIIIa | 1 | 2022 | 1 | 0.210 |
Why?
|
| Ethacrynic Acid | 1 | 2022 | 2 | 0.210 |
Why?
|
| Antifibrinolytic Agents | 1 | 2022 | 3 | 0.210 |
Why?
|
| Models, Biological | 1 | 2006 | 677 | 0.210 |
Why?
|
| Factor IX | 1 | 2022 | 2 | 0.210 |
Why?
|
| Computer Simulation | 4 | 2010 | 362 | 0.190 |
Why?
|
| Skin Neoplasms | 3 | 2011 | 159 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2011 | 122 | 0.190 |
Why?
|
| Drug Design | 2 | 2019 | 162 | 0.190 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2020 | 32 | 0.180 |
Why?
|
| Hydroxamic Acids | 1 | 2019 | 32 | 0.170 |
Why?
|
| Factor VIIa | 1 | 2019 | 2 | 0.170 |
Why?
|
| Blood Coagulation Tests | 1 | 2019 | 5 | 0.170 |
Why?
|
| Factor Xa | 1 | 2019 | 3 | 0.170 |
Why?
|
| Thrombin | 1 | 2019 | 25 | 0.170 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 111 | 0.170 |
Why?
|
| Sulfonamides | 1 | 2019 | 80 | 0.170 |
Why?
|
| Cell Proliferation | 5 | 2020 | 1198 | 0.160 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2017 | 11 | 0.150 |
Why?
|
| Skin Aging | 1 | 2016 | 10 | 0.140 |
Why?
|
| Flavanones | 1 | 2016 | 8 | 0.140 |
Why?
|
| Sunscreening Agents | 1 | 2016 | 9 | 0.140 |
Why?
|
| Hydrogen Bonding | 2 | 2007 | 132 | 0.140 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2015 | 7 | 0.130 |
Why?
|
| Carbonic Anhydrase II | 1 | 2015 | 3 | 0.130 |
Why?
|
| Keratinocytes | 1 | 2016 | 66 | 0.130 |
Why?
|
| Bile Acids and Salts | 1 | 2015 | 33 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 99 | 0.130 |
Why?
|
| Dizocilpine Maleate | 1 | 2015 | 48 | 0.130 |
Why?
|
| Ultraviolet Rays | 1 | 2016 | 117 | 0.130 |
Why?
|
| Protein Structure, Secondary | 2 | 2006 | 183 | 0.130 |
Why?
|
| Piperidines | 1 | 2015 | 77 | 0.130 |
Why?
|
| Antigen-Presenting Cells | 1 | 2014 | 30 | 0.120 |
Why?
|
| Protein Conformation | 2 | 2006 | 389 | 0.120 |
Why?
|
| Structure-Activity Relationship | 4 | 2019 | 409 | 0.120 |
Why?
|
| Mutation | 2 | 2017 | 1095 | 0.120 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 70 | 0.120 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2015 | 137 | 0.120 |
Why?
|
| Bibenzyls | 1 | 2014 | 4 | 0.120 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 18 | 0.120 |
Why?
|
| Thiazoles | 1 | 2014 | 74 | 0.120 |
Why?
|
| Glycyrrhiza | 1 | 2013 | 1 | 0.120 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2013 | 2 | 0.120 |
Why?
|
| Signal Transduction | 2 | 2014 | 1908 | 0.120 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2013 | 31 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 628 | 0.120 |
Why?
|
| Pyridines | 1 | 2014 | 116 | 0.110 |
Why?
|
| Mice | 8 | 2020 | 5913 | 0.110 |
Why?
|
| Isoflavones | 1 | 2013 | 129 | 0.110 |
Why?
|
| Binding Sites | 4 | 2017 | 651 | 0.110 |
Why?
|
| Melanoma | 1 | 2013 | 96 | 0.110 |
Why?
|
| DNA | 1 | 2015 | 574 | 0.100 |
Why?
|
| Xanthenes | 1 | 2011 | 11 | 0.100 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 357 | 0.100 |
Why?
|
| Epidermis | 1 | 2011 | 24 | 0.100 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 22 | 0.100 |
Why?
|
| Sunlight | 1 | 2011 | 47 | 0.100 |
Why?
|
| Cell Line, Tumor | 5 | 2020 | 2231 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 103 | 0.100 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2011 | 14 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 93 | 0.100 |
Why?
|
| Flavonols | 1 | 2011 | 16 | 0.100 |
Why?
|
| Flavonoids | 1 | 2011 | 87 | 0.100 |
Why?
|
| Phosphatidylinositols | 1 | 2010 | 12 | 0.090 |
Why?
|
| Inositol | 1 | 2010 | 21 | 0.090 |
Why?
|
| Mice, Nude | 3 | 2020 | 337 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 259 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 169 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2010 | 54 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2015 | 426 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 3 | 2017 | 408 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 1502 | 0.080 |
Why?
|
| Brain | 1 | 2015 | 1346 | 0.070 |
Why?
|
| Solubility | 1 | 2007 | 118 | 0.070 |
Why?
|
| Solvents | 1 | 2007 | 99 | 0.070 |
Why?
|
| Protein Subunits | 1 | 2007 | 87 | 0.070 |
Why?
|
| Molecular Conformation | 1 | 2007 | 152 | 0.070 |
Why?
|
| Protons | 1 | 2007 | 84 | 0.070 |
Why?
|
| Phosphorylation | 3 | 2016 | 928 | 0.070 |
Why?
|
| Dimerization | 1 | 2006 | 112 | 0.070 |
Why?
|
| Protein Binding | 2 | 2020 | 972 | 0.070 |
Why?
|
| Blotting, Western | 3 | 2013 | 859 | 0.070 |
Why?
|
| Membrane Potentials | 1 | 2006 | 223 | 0.070 |
Why?
|
| Amino Acids | 1 | 2006 | 145 | 0.060 |
Why?
|
| Alanine | 1 | 2005 | 30 | 0.060 |
Why?
|
| Threonine | 1 | 2005 | 25 | 0.060 |
Why?
|
| Bacteriorhodopsins | 1 | 2005 | 36 | 0.060 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 91 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2006 | 289 | 0.060 |
Why?
|
| Chick Embryo | 2 | 2014 | 74 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 2 | 2016 | 35 | 0.060 |
Why?
|
| Carbon | 1 | 2005 | 105 | 0.060 |
Why?
|
| Oxygen | 1 | 2005 | 207 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2005 | 207 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 1180 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2014 | 399 | 0.050 |
Why?
|
| Fibrin | 1 | 2022 | 10 | 0.050 |
Why?
|
| Patents as Topic | 1 | 2022 | 14 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2022 | 45 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2013 | 326 | 0.050 |
Why?
|
| Quercetin | 2 | 2011 | 45 | 0.050 |
Why?
|
| Enzyme Assays | 1 | 2020 | 12 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2011 | 172 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 1609 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 224 | 0.040 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 132 | 0.040 |
Why?
|
| Female | 5 | 2020 | 20969 | 0.040 |
Why?
|
| Biocatalysis | 1 | 2017 | 28 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2017 | 111 | 0.040 |
Why?
|
| Hydrolysis | 1 | 2017 | 99 | 0.040 |
Why?
|
| Magnesium | 1 | 2017 | 97 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2017 | 103 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2017 | 196 | 0.030 |
Why?
|
| Manganese | 1 | 2017 | 87 | 0.030 |
Why?
|
| Mice, Hairless | 1 | 2016 | 7 | 0.030 |
Why?
|
| Microtubules | 1 | 2017 | 120 | 0.030 |
Why?
|
| Butadienes | 1 | 2016 | 29 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2016 | 22 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2017 | 133 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2016 | 22 | 0.030 |
Why?
|
| Luciferases | 1 | 2016 | 63 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 515 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2016 | 82 | 0.030 |
Why?
|
| Nitriles | 1 | 2016 | 69 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2016 | 136 | 0.030 |
Why?
|
| Tritium | 1 | 2015 | 51 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 142 | 0.030 |
Why?
|
| Chorioallantoic Membrane | 1 | 2014 | 11 | 0.030 |
Why?
|
| Piperazines | 1 | 2015 | 111 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 91 | 0.030 |
Why?
|
| Colchicine | 1 | 2014 | 15 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2014 | 47 | 0.030 |
Why?
|
| Laminin | 1 | 2014 | 61 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 69 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 98 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 113 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 59 | 0.030 |
Why?
|
| Glycyrrhizic Acid | 1 | 2013 | 4 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2014 | 73 | 0.030 |
Why?
|
| Tubulin | 1 | 2014 | 88 | 0.030 |
Why?
|
| Water | 1 | 2016 | 296 | 0.030 |
Why?
|
| Collagen | 1 | 2014 | 172 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 131 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 251 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 448 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 219 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2013 | 212 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 502 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2014 | 305 | 0.030 |
Why?
|
| Cell Line | 1 | 2016 | 1354 | 0.030 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2011 | 9 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2011 | 35 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 661 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 149 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 172 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 571 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2011 | 104 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1015 | 0.020 |
Why?
|
| Static Electricity | 1 | 2010 | 78 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2010 | 167 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2010 | 212 | 0.020 |
Why?
|
| Ligands | 1 | 2010 | 349 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 893 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 1518 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 3483 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 935 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1398 | 0.020 |
Why?
|
| Male | 1 | 2013 | 20025 | 0.010 |
Why?
|